health · HHS-NIH11

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

National Institutes of Health · PAR-25-026

149 days left

Deadline

January 7, 2027

GRANTQUICK SUMMARYPlain-English Overview

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required). National Institutes of Health. The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation... Funding amounts not specified.

Who Should Apply

Independent school districts, Small businesses, For-profit organizations, Special district governments, Nonprofits (non-501c3) (+10 more)

Who Should NOT Apply

Organizations not matching the eligible applicant types listed above

Key Requirements (Plain English)

•Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Is...
•Deadline: 2027-01-07

💡 GrantQuick Tip

Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.

Competitiveness: Moderate to high — federal grants are always competitive

What This Grant Funds

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Attachments

PDF

PAR-25-026 Full Announcement Text

PAR-25-026-Full-Announcement.html

Who Can Apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Eligible Applicant Types

Independent School DistrictsSmall BusinessesFor-Profit OrganizationsSpecial District GovernmentsNonprofits without 501(c)(3)501(c)(3) NonprofitsCity/Township GovernmentsFederally Recognized Tribal GovernmentsOther Tribal OrganizationsPublic Colleges & UniversitiesPublic And Indian Housing AuthoritiesState GovernmentsPrivate Colleges & UniversitiesCounty GovernmentsOther (see NOFO for details)

Funding Details

Cost Sharing Required?: No
Funding Instrument: grant

Key Dates

Posted: December 5, 2024

Application Deadline: January 7, 2027 (149 days remaining)

Agency Contact

NIH Grants Information grantsinfo@nih.gov

grantsinfo@nih.gov

Ready to apply?

View the full NOFO and submit your application on Grants.gov

View on Grants.gov